^
Association details:
| Biomarker: | BAP1 I696T |
|---|---|
| Cancer: | Kidney Cancer |
| Drug: | sunitinib (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mucinous tubular and spindle-cell carcinoma of the kidney: Clinical features, genomic profiles, and treatment outcomes.
Published date:
05/02/2020
Excerpt:
Four patients received systemic therapy with time to treatment failure ≤ 6 months across different agents with the exception of one patient with prolonged response on sunitinib (30.6 months)....The tumor of the patient who achieved long lived response on sunitinib harbored a total of 8 mutations including BAP1(I696T) missense mutation.
DOI:
10.1016/j.clgc.2019.04.006